Bg pattern

SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet:information for the user

Sibudel 250 mg solution for injection in a pre-filled syringe EFG

fulvestrant

Read all of this leaflet carefully before you start using this medicine,because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only, and you should not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
    • If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Sibudel and what is it used for
  2. What you need to know before you use Sibudel
  3. How to use Sibudel
  4. Possible side effects
  5. Storage of Sibudel
  6. Contents of the pack and further information

1. What is Sibudel and what is it used for

Sibudel contains the active substance fulvestrant, which belongs to the group of estrogen blockers. Estrogens, a type of female sex hormone, may be involved in the development of breast cancer in some cases.

Sibudel is used:

  • alone, to treat postmenopausal women with a type of breast cancer called hormone receptor-positive breast cancer, which is locally advanced or has spread to other parts of the body (metastatic) or,
  • in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer, which is locally advanced or has spread to other parts of the body (metastatic). Women who have not reached menopause will also be treated with a medicine called a luteinizing hormone-releasing hormone (LHRH) agonist.

Fulvestrant may be administered in combination with palbociclib. It is important that you also read the package leaflet for palbociclib. If you have any questions about palbociclib, ask your doctor.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Sibudel

Do not useSibudel:

  • if you are allergic to fulvestrant or any of the other ingredients of this medicine (listed in section 6)
  • if you are pregnant or breastfeeding (see section "Pregnancy and breastfeeding")
  • if you have severe liver problems

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting Sibudel if any of the following apply to you:

  • kidney or liver problems
  • low platelet count (which helps blood to clot) or bleeding disorders
  • previous blood clot problems
  • osteoporosis (loss of bone density)
  • alcoholism (see section "Sibudel contains ethanol 96% (alcohol)").

The efficacy and safety of fulvestrant (as monotherapy or in combination with palbociclib) have not been studied in patients with critical visceral disease.

Children and adolescents

Sibudel is not indicated for children and adolescents under 18 years of age.

Using Sibudelwithother medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In particular, you should tell your doctor if you are using anticoagulants (medicines to prevent blood clots).

Pregnancy andbreastfeeding

You should not use Sibudel if you are pregnant. If you can become pregnant, you should use an effective contraceptive method while being treated with Sibudel and for 2 years after your last dose.

You should not breastfeed while being treated with Sibudel.

Driving and using machines

Sibudel is not expected to affect your ability to drive or use machines. However, if you feel tired after treatment, do not drive or use machines.

Sibudelcontains ethanol 96% (alcohol)

This medicine contains 474 mg of alcohol (ethanol) in each 5 ml pre-filled syringe, which corresponds to 94.8 mg/ml. The amount in a 10 ml dose of this medicine is equivalent to less than 24 ml of beer or 10 ml of wine.

The small amount of alcohol in this medicine will not have a notable effect.

Sibudelcontains benzyl alcohol

This medicine contains 500 mg of benzyl alcohol in each 5 ml pre-filled syringe, equivalent to 100 mg per ml.

Benzyl alcohol may cause allergic reactions.

Talk to your doctor or pharmacist if you have liver or kidney disease. This is because large amounts of benzyl alcohol can accumulate in the body and cause side effects (metabolic acidosis).

Sibudelcontains benzyl benzoate

This medicine contains 750 mg of benzyl benzoate in each 5 ml pre-filled syringe, equivalent to 150 mg per ml.

3. How to use Sibudel

Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

The recommended dose is 500 mg of fulvestrant (two 250 mg/5ml injections) administered once a month with an additional dose of 500 mg administered 2 weeks after the initial dose.

Your doctor or nurse will administer Sibudel by slow intramuscular injection into each of your buttocks.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You may need urgent medical attention if you experience any of the following side effects:

  • allergic reactions (hypersensitivity), including swelling of the face, lips, tongue, and/or throat, which may be signs of anaphylactic reactions
  • thromboembolism (increased risk of blood clots)*
  • liver inflammation (hepatitis)
  • liver failure.

Tell your doctor, pharmacist, or nurse if you notice any of the following side effects:

Side effects reported in patients treated with fulvestrant as monotherapy:

Very common:may affect more than 1 in 10 people

  • injection site reactions, such as pain and/or inflammation
  • abnormal liver enzyme levels (in blood tests)*
  • nausea (feeling sick)
  • weakness, fatigue*
  • joint and musculoskeletal pain
  • hot flashes
  • skin rash
  • allergic reactions (hypersensitivity), including swelling of the face, lips, tongue, and/or throat

All other side effects:

Common:may affect up to 1 in 10 people

  • headache
  • vomiting, diarrhea, or loss of appetite*
  • urinary tract infections
  • back pain*
  • increased bilirubin levels (a bile pigment produced by the liver).
  • thromboembolism (increased risk of blood clots)*
  • decreased platelet count (thrombocytopenia)
  • vaginal bleeding
  • lower back pain radiating to one leg (sciatica)
  • sudden weakness, numbness, tingling, or loss of movement in your leg, especially on one side of the body, sudden problems with walking or balance (peripheral neuropathy)

Uncommon:may affect up to 1 in 100 people

  • thick, white, vaginal discharge and candidiasis (infection)
  • hematoma and bleeding at the injection site
  • increased gamma-GT, a liver enzyme identified in a blood test
  • liver inflammation (hepatitis)
  • liver failure
  • numbness, tingling, and pain
  • anaphylactic reactions

*Includes side effects for which the exact role of Sibudel cannot be evaluated due to the underlying disease.

Side effects reported in patients treated with fulvestrant in combination with palbociclib:

Very common:may affect more than 1 in 10 people

  • decreased neutrophil count (neutropenia)
  • decreased white blood cell count (leucopenia)
  • infections
  • fatigue
  • nausea
  • reduced red blood cell count (anemia)
  • inflammation or ulceration of the mouth
  • diarrhea
  • decreased platelet count (thrombocytopenia)
  • vomiting
  • hair loss
  • rash
  • loss of appetite
  • fever

Common:may affect up to 1 in 10 people

  • feeling weak
  • increased liver enzyme levels
  • loss of taste
  • nasal bleeding
  • excessive tearing
  • dry skin
  • blurred vision
  • dry eyes

Uncommon:may affect up to 1 in 100 people

fever with other signs of infection (febrile neutropenia).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Sibudel

Keepthis medicineout of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or on the label of the syringes after EXP. The expiry date refers to the last day of the month shown.

Do not use this medicine if you notice particles or discoloration before administration.

Store and transport in a refrigerator (between 2°C and 8°C).

Temperature deviations outside the range of 2°C to 8°C should be controlled. This includes avoiding storage at temperatures above 25°C, and not exceeding a period of 4 months, during which the average storage temperature of the medicine is below 25°C (but above 2°C to 8°C). After temperature deviations, the medicine should be returned immediately to the recommended storage conditions (store and transport in a refrigerator between 2°C and 8°C). Temperature deviations have a cumulative effect on the quality of the medicine, and the 4-month period should not exceed the 2-year shelf life of Sibudel. Exposure to temperatures below 2°C will not damage the medicine, as long as it is not stored below -20°C.

Keep the pre-filled syringe in the original packaging to protect it from light.

Your healthcare professional will be responsible for the proper storage, use, and disposal of Sibudel.

This medicine may pose a risk to the aquatic environment. Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and further information

Composition of Sibudel

  • The active substance is fulvestrant. Each pre-filled syringe contains 250 mg of fulvestrant. Each ml of solution contains 50 mg of fulvestrant.
  • The other ingredients (excipients) are ethanol (96%), benzyl alcohol, benzyl benzoate, and refined castor oil.

Appearance of the product and pack contents

Sibudel is a viscous, clear, colorless to yellow solution in a pre-filled syringe equipped with a Luer-Lock connector containing 5 ml of injectable solution. Two syringes should be administered to receive the recommended monthly dose of 500 mg.

Sibudel is available in 2 formats:

  • 1 pack containing 1 glass pre-filled syringe and 1 needle with a safety system for connection to the syringe body.
  • 1 pack containing 2 glass pre-filled syringes and 2 needles with a safety system for connection to the syringe body.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Marketing authorisation holder

Teva Pharma, S.L.U.

C/ Anabel Segura, 11. Edificio Albatros B, 1ª planta

28108 Alcobendas, Madrid

Spain

Manufacturer

Pliva Croatia Ltd.

Prilaz baruna Filipovica 25

10000 Zagreb

Croatia

This medicine is authorised in the Member States of the European Economic Area under the following names:

Germany: Fulvestrant AbZ 250 mg Injektionslösung in einer Fertigspritze

Spain: Sibudel 250 mg solución inyectable en jeringa precargada EFG

Date of last revision of thisleaflet: July 2025

Other sources of information

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/

You can access detailed and up-to-date information about this medicine by scanning the QR code included in the packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/80999/P_80999.html

QR code + URL

----------------------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Sibudel 500 mg (2 x 250 mg/5 ml solution for injection) should be administered using two pre-filled syringes (see section 3).

Administration instructions

Administer the injection according to local guidelines for intramuscular injection of large volumes.

NOTE: Due to the proximity of the sciatic nerve, caution should be exercised when injecting Sibudel into the dorsogluteal area (see section 4.4).

Warning - Do not sterilize the needle with a safety system in an autoclave before use. Hands should remain behind the needle at all times during use and disposal.

For each of the two syringes:

  • Remove the glass syringe body from the tray and check that it is not damaged.
  • Open the outer packaging of the needle with a safety system.
  • Before administration, visually inspect the parenteral solutions for particles and discoloration.
  • Hold the syringe in a vertical position, gripping the ribbed part (C). With the other hand, grip the cap (A) and carefully tilt it back and forth until it comes off and can be removed (see Figure 1).

Figure 1

Hand holding an injection device with a cylinder and a connector, showing parts A and C labeled in the diagram

  • Remove the cap (A) by pulling upwards. To maintain sterility, DO NOT TOUCH THE TIP OF THE SYRINGE (Luer-Lock) (B) (see Figure 2).

Figure 2

Hand holding a device with a plunger and a transparent cylinder, arrow indicating direction and labels A, B, C pointing to parts

  • Attach the needle with a safety system to the Luer-Lock and screw it on until it is firmly attached (see Figure 3).
  • Check that the needle is attached to the Luer connector.
  • Take the loaded syringe to the administration site.
  • Pull the protective cap straight off the needle to avoid damaging the tip.

Figure 3

Hand holding a syringe with a needle and another hand pinching the skin preparing for injection, arrow indicates direction

  • Remove any excess air from the syringe.
  • Administer slowly via intramuscular injection into the buttock (gluteal area) (1-2 minutes/injection). For greater comfort, the position of the needle with the bevel upwards has the same orientation as the lever raised (see Figure 4).

Figure 4

Hypodermic needle connected to a syringe showing bevel and sharp end for subcutaneous injection

  • After injection, immediately touch the lever with your finger to activate the protective mechanism (see Figure 5).

NOTE: Activate away from your body and others. Listen for the click and visually confirm that the needle tip is fully protected.

Figure 5

Hand holding a syringe with a needle inserted into the skin, showing angle of injection and direction of the black arrow

Disposal

The pre-filled syringes are for singleuse only.

This medicine may pose a risk to the aquatic environment. Disposal of unused medicine and all materials that have come into contact with it will be carried out in accordance with local regulations.

Online doctors for SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe

Discuss questions about SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (21)
Doctor

Giorgi Eremeishvili

Urology 22 years exp.

Giorgi Eremeishvili is a top-category urologist, a Candidate of Medical Sciences, and a licensed physician in Spain. He provides expert assistance in the diagnosis and treatment of a wide range of urological conditions in both men and women, employing a comprehensive approach and evidence-based principles.

Key areas of expertise:

  • Erectile dysfunction, decreased libido, premature ejaculation.
  • Male infertility: comprehensive diagnosis and modern treatment methods.
  • Prostate gland diseases: acute and chronic prostatitis, prostatic adenoma (benign prostatic hyperplasia), prostate cancer.
  • Inflammatory diseases of the genitourinary system: acute and chronic cystitis, pyelonephritis, epididymitis, orchitis, urethritis.
  • Sexually transmitted infections (STIs): chlamydia, ureaplasmosis, mycoplasmosis, gardnerellosis, candidiasis, herpetic infections, HPV, CMV, trichomoniasis, and others.
  • Urination disorders: urinary retention, frequent urination, urinary incontinence, overactive bladder, neurogenic bladder.
  • Neoplasms: cysts, tumors of the kidneys, bladder, testicles, prostate gland (including prostate cancer).
  • Surgical interventions: determining indications and selecting optimal minimally invasive methods.

Dr. Eremeishvili applies an integrated approach to each case. This includes thorough preoperative preparation, postoperative observation, and regular dynamic follow-up during the treatment process to achieve the best possible outcomes. All diagnostic and therapeutic recommendations are based on current evidence-based medicine and comply with the recommendations of the European Association of Urology, guaranteeing high-quality and effective care.

If you are seeking qualified assistance in diagnosing or treating urological conditions, book an online consultation with Dr. Giorgi Eremeishvili. Get expert support, accurate diagnosis, and a personalized treatment plan from the comfort of your home.

Camera Book a video appointment
€60
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60
5.0 (29)
Doctor

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

  • Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
  • Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
  • Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
  • Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
  • General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
  • Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
  • Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
  • Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe?
SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe?
The active ingredient in SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe is fulvestrant. This information helps identify medicines with the same composition but different brand names.
How much does SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe cost in pharmacies?
The average pharmacy price for SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe is around 225.7 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe?
SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe is manufactured by Teva Pharma S.L.U.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to SIBUDEL 250 mg Injectable Solution in Pre-filled Syringe?
Other medicines with the same active substance (fulvestrant) include AFULTRANT 250 mg Injectable Solution in Pre-filled Syringe, AMBIFUL 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, FASLODEX 250 mg/5 ml INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media